RE:RE:Valeant now targeting small acquisitionsMy dear friend if SBM has a block of shares sufficient (insiders and major investors) to avoid a takeover they can negociate a fair price for the portfolio of products under development and develop in the coming years. Everything has a price.
Another source: Zacks Equity Research, January 09, 2015 :
After a failed bid to acquire Allergan in 2014, Valeant now aims to focus on building existing platforms, adding new platforms in fast-growing markets or acquiring tail products with extremely high internal rate of return or fast payback periods in developed markets in 2015. The strategy for emerging markets is to focus on branched generics and OTC's, and expanding in Asia, Middle East and latin America.